1-5 of 5
Junji Uchida
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract A126: Acquired resistance to trastuzumab/pertuzumab, or to T-DM1 in vivo can be overcome by HER2 inhibition with TAS0728

Hiroki Irie, Rumi Kawabata, Yayoi Fujioka, Fumio Nakagawa, Hideki Nagase, Hiraku Itadani, Kimihiro Ito, Junji Uchida, Shuichi Ohkubo, Kenichi Matsuo, Takeshi Sagara, Teruhiro Utsugi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A126.
https://doi.org/10.1158/1535-7163.TARG-19-A126
Published: 01 December 2019
View article titled, Abstract A126: Acquired resistance to trastuzumab/pertuzumab, or to T-DM1 <em>in vivo</em> can be overcome by HER2 inhibition with TAS0728
Journal Articles

Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models

Hiroki Irie, Kei Oguchi, Kimihiro Ito, Yayoi Fujioka, Yuichi Kawai, Tadashi Shimamura, Hikari Araki, Akio Fujioka, Fumio Nakagawa, Rumi Kawabata, Hideki Nagase, Takeshi Sagara, Junji Uchida, Kenichi Matsuo, Teruhiro Utsugi, Yoshikazu Iwasawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B179.
https://doi.org/10.1158/1535-7163.TARG-17-B179
Published: 01 January 2018
View article titled, Abstract B179: TAS0728, a HER2-selective covalent inhibitor, demonstrates potent antitumor effect as a single agent and in combination with anti-HER2 antibodies in HER2-overexpressed tumor models
Journal Articles

Abstract A149: Quantitative detection of the EGFR activating and resistance mutations in plasma DNA of lung cancer patients.

Kazuya Taniguchi, Junji Uchida, Kukita Yoji, Kazumi Nishino, Toru Kumagai, Yuki Akazawa, Takako Okuyama, Jiro Okami, Masahiko Higashiyama, Fumio Imamura, Kikuya Kato
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A149.
https://doi.org/10.1158/1535-7163.TARG-11-A149
Published: 12 November 2011
View article titled, Abstract A149: Quantitative detection of the EGFR activating and resistance mutations in plasma DNA of lung cancer patients.
Journal Articles

Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with HER2 Amplification

Junko Tanizaki, Isamu Okamoto, Ken Takezawa, Sayaka Tsukioka, Junji Uchida, Mamoru Kiniwa, Masahiro Fukuoka, Kazuhiko Nakagawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (5): 1198–1207.
https://doi.org/10.1158/1535-7163.MCT-10-0045
Published: 09 May 2010
View article titled, Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with <em>HER2</em> Amplification
Open the PDF for Synergistic Antitumor Effect of S-1 and HER2-Targeting Agents in Gastric Cancer with <em>HER2</em> Amplification in another window
Journal Articles

Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase

Takafumi Okabe, Isamu Okamoto, Sayaka Tsukioka, Junji Uchida, Tsutomu Iwasa, Takeshi Yoshida, Erina Hatashita, Yuki Yamada, Taroh Satoh, Kenji Tamura, Masahiro Fukuoka, Kazuhiko Nakagawa
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (3): 599–606.
https://doi.org/10.1158/1535-7163.MCT-07-0567
Published: 17 March 2008
View article titled, Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase
Open the PDF for Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase in another window